Halozyme Therapeutics, Inc.
HALO
$64.66
-$1.88-2.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.76% | 22.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.76% | 22.98% | |||
| Cost of Revenue | 56.37% | -10.21% | |||
| Gross Profit | 0.86% | 31.01% | |||
| SG&A Expenses | 10.75% | -1.77% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.60% | -0.04% | |||
| Operating Income | 7.65% | 43.03% | |||
| Income Before Tax | 6.84% | 42.49% | |||
| Income Tax Expenses | 9.94% | 54.58% | |||
| Earnings from Continuing Operations | 6.09% | 39.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.09% | 39.85% | |||
| EBIT | 7.65% | 43.03% | |||
| EBITDA | 6.95% | 37.98% | |||
| EPS Basic | 9.83% | 42.02% | |||
| Normalized Basic EPS | 10.60% | 46.43% | |||
| EPS Diluted | 7.52% | 43.01% | |||
| Normalized Diluted EPS | 8.44% | 47.08% | |||
| Average Basic Shares Outstanding | -3.40% | -1.52% | |||
| Average Diluted Shares Outstanding | -1.47% | -1.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||